Policy for scientific publications and responsible clinical trial data sharing

Lundbeck’s mission is to improve the quality of life of people suffering from psychiatric and neurological disorders. As a pharmaceutical company, Lundbeck considers the sharing of information from company-sponsored clinical trials to be an important part of fulfilling this mission. Lundbeck publishes the results from our research and clinical studies in scientific journals and presents these results at scientific conferences. Lundbeck also discloses clinical trial information and results summaries in public registries and shares clinical data. The Lundbeck policy for scientific publications and responsible clinical trial data sharing covers all scientific publications authored by Lundbeck and clinical trial data sharing for trials sponsored by H. Lundbeck A/S.

Lundbeck publishes the results from clinical studies of its products and drug development candidates, irrespective of whether the results are positive or negative, and acknowledges a special obligation to publish data related to patient safety.

Per EFPIA/PhRMA´s commitment, Lundbeck will submit for publication the results of Lundbeck-sponsored clinical studies, primarily in peer-reviewed journals, or as abstracts, posters, or other presentations at scientific meetings. Publication activities will be undertaken responsibly and ethically to ensure that all relevant information is communicated clearly and in a timely manner. Wherever possible, manuscripts will be submitted no later than 18 months after study completion for approved products. The commitment to publish also applies to drug development compounds for which development has been discontinued. In situations when the data are of limited scientific or clinical value, or in the case of multiple journal rejections, posting results on a public clinical trial registry site may be an option for disclosure.

Lundbeck encourages publication of the results from drug discovery. The timing of nonclinical publications will take into consideration intellectual property rights as well as legislation and national practices in patent law.

When entering into research and development collaborations, it is Lundbeck’s commitment to maintain ethical and transparent publication practices, which is in accordance with Good Publication Practice 3 (www.ismpp.org/gpp3).


Lundbeck respects the privacy of the relationship between patients and healthcare professionals and is committed to ensuring that the process of scientific publication and clinical trial data sharing do not breach patient confidentiality.

Cookie Policy
You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.